MKI67 and neoplasm: Despite the fact that response differences between individual patient WTCs do exist, the three topoisomerase II inhibitors doxorubicin, epirubicin, and mitoxantrone showed robust treatment responses irrespectively of prognostic parameters including ER status, tumor sizes, nodal status, and Ki67 (SI Appendix, Fig. S6 I–K).